Tina Fanoe - Novozymes Executive Vice President Agriculture & Bioenergy

NVZMY Stock  USD 58.24  0.78  1.32%   

President

Ms. Tina Sejersgaard Fanoe was Executive Vice President, Agriculture Bioenergy at Novozymes AS since February 8, 2016. She is also Board Member of DLF AS. Previously, she was Vice President of Sales at the Company. She holds a MS in Chemical Engineering from the Technical University of Denmark, as well as a Bachelor of Arts degree in philosophy and education from Copenhagen University, Denmark. She started her career with the company in 1993 and has held various positions within RD, Marketing, Business Development and Sales. since 2016.
Age 54
Tenure 8 years
Phone45 44 46 00 00
Webhttps://www.novozymes.com

Novozymes Management Efficiency

The company has return on total asset (ROA) of 0.1062 % which means that it generated a profit of $0.1062 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2789 %, meaning that it generated $0.2789 on every $100 dollars invested by stockholders. Novozymes' management efficiency ratios could be used to measure how well Novozymes manages its routine affairs as well as how well it operates its assets and liabilities.
Novozymes AS has accumulated 7.31 B in total debt with debt to equity ratio (D/E) of 0.59, which is about average as compared to similar companies. Novozymes AS has a current ratio of 1.18, suggesting that it may not be capable to disburse its financial obligations in time and when they become due. Debt can assist Novozymes until it has trouble settling it off, either with new capital or with free cash flow. So, Novozymes' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Novozymes AS sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Novozymes to invest in growth at high rates of return. When we think about Novozymes' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

PRESIDENT Age

Francesco MaioneAir Products and
N/A
Sean MajorAir Products and
60
Ramaparasad VadlamannatiPPG Industries
61
Michael SimmonsAlbemarle Corp
60
Scott TozierAlbemarle Corp
58
Allen MistysynSherwin Williams Co
55
Gregory YepInternational Flavors Fragrance
59
Louie DAmicoGivaudan SA ADR
62
Anne FoulkesPPG Industries
61
Fabienne LecorvaisierAir Liquide SA
61
Mary GarceauSherwin Williams Co
51
Rebecca LiebertPPG Industries
53
Glenn RichterInternational Flavors Fragrance
62
Maurizio VolpiGivaudan SA ADR
54
Heidi PetzSherwin Williams Co
49
Brian GalovichAir Products and
51
Victoria BrifoAir Products and
55
Timothy KnavishPPG Industries
58
Brian GallagherSherwin Williams Co
52
Michael CroccoAir Products and
58
Melissa SchaefferAir Products and
44
Novozymes AS produces and sells industrial enzymes, microorganisms, and probiotics in Europe, the Middle East, Africa, North America, the Asia Pacific, and Latin America. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark. Novozymes Unspn is traded on OTC Exchange in the United States. Novozymes AS [NVZMY] is a Pink Sheet which is traded between brokers as part of OTC trading.

Management Performance

Novozymes AS Leadership Team

Elected by the shareholders, the Novozymes' board of directors comprises two types of representatives: Novozymes inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novozymes. The board's role is to monitor Novozymes' management team and ensure that shareholders' interests are well served. Novozymes' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novozymes' outside directors are responsible for providing unbiased perspectives on the board's policies.
Pedro Fernandes, Head America
Tobias Bjorklund, Head of Investor Relations
Ester Baiget, Pres CEO
Tue Micheelsen, VP Marketing
Sebastian Sderberg, VP Acquisitions
Tina Fanoe, Executive Vice President Agriculture & Bioenergy
Graziela Malucelli, Supply Operations
Anders Lund, Executive Vice President Household Care & Technical Industries
Morten Rasmussen, Sustainability People
MSc MSc, Ex CFO

Novozymes Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Novozymes a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Novozymes Pink Sheet Analysis

When running Novozymes' price analysis, check to measure Novozymes' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novozymes is operating at the current time. Most of Novozymes' value examination focuses on studying past and present price action to predict the probability of Novozymes' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novozymes' price. Additionally, you may evaluate how the addition of Novozymes to your portfolios can decrease your overall portfolio volatility.